313397-13-6

Reversan represents a new class of nontoxic MRP1 inhibitor, which may be clinically useful for the treatment of neuroblastoma.

Selective inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp). Increases the sensitivity of MRP1-overexpressing tumor cells (MCF7/VP) to doxorubicin , vincristine and etoposide by 3.8-, 14.6- and 11.6-fold respectively. Increases the efficacy of vincristine and etoposide in murine models of neuroblastoma in vivo . Displays at activity on MRP2, MRP3, MRP5 and MRP5 transporters.

Store at -20°C